A Phase II Randomized Trial to Explore the Potential for Pharmacokinetic Drug–Drug Interactions with Stiripentol or Valproate when Combined with Cannabidiol in Patients with Epilepsy

Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study

(2019) Elizabeth Thiele et al.   EPILEPSIA

Pharmacokinetics and Tolerability of Multiple Doses of Pharmaceutical-Grade Synthetic Cannabidiol in Pediatric Patients with Treatment-Resistant Epilepsy

(2019) James W. Wheless et al.   CNS DRUGS

Cytochrome P450 Structure, Function and Clinical Significance: A Review

(2018) Palrasu Manikandan et al.   CURRENT DRUG TARGETS

Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: Expanded access program results

(2018) Jerzy P. Szaflarski et al.   EPILEPSIA

Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial

(2018) Elizabeth A Thiele et al.   LANCET

Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome

(2018) Orrin Devinsky et al.   NEUROLOGY

Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome

(2018) Orrin Devinsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects

(2018) Lesley Taylor et al.   CNS DRUGS

Current Treatment Strategies and Future Treatment Options for Dravet Syndrome

(2018) Julie Ziobro et al.   Current Treatment Options in Neurology

Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial

(2018) Orrin Devinsky et al.   EPILEPSIA

Interactions between cannabidiol and commonly used antiepileptic drugs

(2017) Tyler E. Gaston et al.   EPILEPSIA

Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome

(2017) Orrin Devinsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Expert Opinion on the Management of Lennox–Gastaut Syndrome: Treatment Algorithms and Practical Considerations

(2017) J. Helen Cross et al.   Frontiers in Neurology

Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy

(2015) Alexandra L. Geffrey et al.   EPILEPSIA

Lennox-Gastaut syndrome: A consensus approach to differential diagnosis

(2014) Blaise F. D. Bourgeois et al.   EPILEPSIA

Cannabidiol Is a Potent Inhibitor of the Catalytic Activity of Cytochrome P450 2C19

(2013) Rongrong Jiang et al.   Drug Metabolism and Pharmacokinetics

When is Protein Binding Important?*

(2013) Jules Heuberger et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Valproic acid pathway

(2013) Yogita Ghodke-Puranik et al.   Pharmacogenetics and Genomics

The Columbia–Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings From Three Multisite Studies With Adolescents and Adults

(2011) Kelly Posner et al.   AMERICAN JOURNAL OF PSYCHIATRY

Cannabidiol, a Major Phytocannabinoid, As a Potent Atypical Inhibitor for CYP2D6

(2011) S. Yamaori et al.   DRUG METABOLISM AND DISPOSITION

Definition and natural history of Lennox-Gastaut syndrome

(2011) Peter R. Camfield   EPILEPSIA

The core Dravet syndrome phenotype

(2011) Charlotte Dravet   EPILEPSIA

Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes

(2011) Rongrong Jiang et al.   LIFE SCIENCES

Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: Role of phenolic hydroxyl groups in the resorcinol moiety

(2011) Satoshi Yamaori et al.   LIFE SCIENCES